@article{10.11648/j.wjfst.20220602.14,
  author = {Josep Sola and Josep Manuel Llabres and Alba Novella and Angel Menargues},
  title = {In vitro Protective Effect of Berdetox® on Fatty Acid Induced Steatosis in HepG2 Cells},
  journal = {World Journal of Food Science and Technology},
  volume = {6},
  number = {2},
  pages = {47-57},
  doi = {10.11648/j.wjfst.20220602.14},
  url = {https://doi.org/10.11648/j.wjfst.20220602.14},
  eprint = {https://article.sciencepublishinggroup.com/pdf/10.11648.j.wjfst.20220602.14},
  abstract = {There is a demand in the market of products for liver health, therefore, Plameca has developed a formula that contains berberine and curcumin. There is existing evidence for those ingredients on their beneficial effect in non-alcoholic fatty liver diseases (NAFLD). In addition, the formula contains other traditionally used active ingredients with health benefits for the liver. The objective of the present work was a primary evaluation of the effects of the dietary supplement syrup Berdetox® on the prevention and the reversion of mild steatosis in the in vitro HepG2 cell model. HepG2 cells were incubated with a mixture of oleic acid and palmitic acid at a respective proportion of 2:1 and a final concentration of 0.25 mM for 24 h to induce steatosis. Cells were exposed to the test syrup 2 h prior and during lipid overload or after removal of the lipid mixture. The intracellular lipid content and the membrane integrity were determined by Nile red and neutral red staining, respectively. The effect of the metabolites of the active components of the syrup was assessed indirectly using the same experimental approach after previous incubation of the syrup with human hepatocytes. The lipid mixture effectively induced steatosis in the HepG2 cells. The intracellular lipid content was reduced dose dependently after simultaneous exposure to test syrup with or without previous incubation with human hepatocytes. However, the reversive effect of the syrup was of the same magnitude than the treatment with incubation medium only. The cell membrane integrity remained unaffected after lipid overload and after the treatment with the test syrup or its excipients. Berdetox® demonstrated a preventive effect against steatosis in HepG2 cells as measured by the reduction of the intracellular lipid content in vitro at in vivo meaningful concentrations of its marker ingredients. The experimental conditions used in this work were based in the induction of mild steatosis as a response to cell overload with a mixture of oleic and palmitic acids at a proportion considered to mimic the reversible initial phase of liver disease. The human hepatic metabolites of the active components showed also equivalent efficacy. The reversive effect of the test ingredients could not be demonstrated because steatosis was reverted by endogenous cell reparation mechanisms.},
 year = {2022}
}

Copy | Download

TY  - JOUR
T1  - In vitro Protective Effect of Berdetox® on Fatty Acid Induced Steatosis in HepG2 Cells
AU  - Josep Sola
AU  - Josep Manuel Llabres
AU  - Alba Novella
AU  - Angel Menargues
Y1  - 2022/06/21
PY  - 2022
N1  - https://doi.org/10.11648/j.wjfst.20220602.14
DO  - 10.11648/j.wjfst.20220602.14
T2  - World Journal of Food Science and Technology
JF  - World Journal of Food Science and Technology
JO  - World Journal of Food Science and Technology
SP  - 47
EP  - 57
PB  - Science Publishing Group
SN  - 2637-6024
UR  - https://doi.org/10.11648/j.wjfst.20220602.14
AB  - There is a demand in the market of products for liver health, therefore, Plameca has developed a formula that contains berberine and curcumin. There is existing evidence for those ingredients on their beneficial effect in non-alcoholic fatty liver diseases (NAFLD). In addition, the formula contains other traditionally used active ingredients with health benefits for the liver. The objective of the present work was a primary evaluation of the effects of the dietary supplement syrup Berdetox® on the prevention and the reversion of mild steatosis in the in vitro HepG2 cell model. HepG2 cells were incubated with a mixture of oleic acid and palmitic acid at a respective proportion of 2:1 and a final concentration of 0.25 mM for 24 h to induce steatosis. Cells were exposed to the test syrup 2 h prior and during lipid overload or after removal of the lipid mixture. The intracellular lipid content and the membrane integrity were determined by Nile red and neutral red staining, respectively. The effect of the metabolites of the active components of the syrup was assessed indirectly using the same experimental approach after previous incubation of the syrup with human hepatocytes. The lipid mixture effectively induced steatosis in the HepG2 cells. The intracellular lipid content was reduced dose dependently after simultaneous exposure to test syrup with or without previous incubation with human hepatocytes. However, the reversive effect of the syrup was of the same magnitude than the treatment with incubation medium only. The cell membrane integrity remained unaffected after lipid overload and after the treatment with the test syrup or its excipients. Berdetox® demonstrated a preventive effect against steatosis in HepG2 cells as measured by the reduction of the intracellular lipid content in vitro at in vivo meaningful concentrations of its marker ingredients. The experimental conditions used in this work were based in the induction of mild steatosis as a response to cell overload with a mixture of oleic and palmitic acids at a proportion considered to mimic the reversible initial phase of liver disease. The human hepatic metabolites of the active components showed also equivalent efficacy. The reversive effect of the test ingredients could not be demonstrated because steatosis was reverted by endogenous cell reparation mechanisms.
VL  - 6
IS  - 2
ER  - 

Copy | Download